Editas Medicine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). 

CEO
Gilmore O’Neill
CEOGilmore O’Neill
Employees
246
Employees246
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2013
Founded2013
Employees
246
Employees246

EDIT Key Statistics

Market cap
226.96M
Market cap226.96M
Price-Earnings ratio
-0.84
Price-Earnings ratio-0.84
Dividend yield
Dividend yield
Average volume
1.96M
Average volume1.96M
High today
$2.47
High today$2.47
Low today
$1.93
Low today$1.93
Open price
$2.00
Open price$2.00
Volume
3.66M
Volume3.66M
52 Week high
$4.54
52 Week high$4.54
52 Week low
$0.9101
52 Week low$0.9101

Stock Snapshot

The current Editas Medicine(EDIT) stock price is $2.33, with a market capitalization of 226.96M. The stock trades at a price-to-earnings (P/E) ratio of -0.84.

During the trading session on 2026-03-09, Editas Medicine(EDIT) shares reached a daily high of $2.47 and a low of $1.93. At a current price of $2.33, the stock is +20.5% higher than the low and still -5.9% under the high.

Trading activity shows a volume of 3.66M, compared to an average daily volume of 1.96M.

Over the past 52 weeks, Editas Medicine(EDIT) stock has traded between a high of $4.54 and a low of $0.91.

Over the past 52 weeks, Editas Medicine(EDIT) stock has traded between a high of $4.54 and a low of $0.91.

EDIT News

Nasdaq 5h
Editas Medicine Reports Q4 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $1 per...

Editas Medicine Reports Q4 Loss, Tops Revenue Estimates
TipRanks 6h
Editas Medicine reports Q4 EPS (6c), consensus (26c)

Reports Q4 revenue $24.741M vs $30.604M last year. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become...

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.